While several countries are relying on Sinovac Biotech’s coronavirus disease 2019 (COVID-19) vaccine to end the pandemic once and for all, concerns regarding the shot’s efficacy continue to shroud the vaccine, which is currently the second most used COVID-19 vaccine product across the globe.
Although the Beijing-based biotech’s vaccine has demonstrated success in clinical trials, efficacy rates have ranged from 50% to as high as 90% across clinical trials conducted in Turkey, Brazil and Indonesia. Sinovac has since kept mum on these data and hasn’t provided explanations or further details on why protection rates vary from study to study.
A report also came in light about scores of Indonesian health workers getting infected despite having received Coronavac injections had drawn concern among countries relying on the Chinese vaccine.
Singapore’s top health officials also cast doubt on effectiveness of China’s Sinovac vaccines for coronavirus.
